Free Trial
→ What President Trump’s Executive Order 14154 means for your money (From Stansberry Research) (Ad)

10 Best Penny Stocks to Buy Now - 3 of 10

Slide 3
Back to 2
Continue to 4
 
Back to 2
Continue to 4
 

Nektar Therapeutics (NASDAQ:NKTR)

Number of Upgrades from Top-Ranked Analysts
5 (in the last 90 days)
Consensus Rating
Buy
Rating Score
3.0
Ratings Breakdown
7 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$4.50 (465.7% Upside)

About Nektar Therapeutics

Nektar Therapeutics logoNektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. More about Nektar Therapeutics
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
4/11/2025Jefferies Financial GroupUpgradeHold ➝ Buy$1.00 ➝ $2.00
3/14/2025OppenheimerUpgradeMarket Perform ➝ Outperform$6.00
3/13/2025William BlairReiterated RatingMarket Perform
3/13/2025HC WainwrightReiterated RatingBuy ➝ Buy$6.50 ➝ $6.50
2/25/2025William BlairReiterated RatingMarket Perform
2/25/2025HC WainwrightReiterated RatingBuy ➝ Buy$6.50 ➝ $6.50
1/13/2025HC WainwrightReiterated RatingBuy ➝ Buy$6.50 ➝ $6.50
1/8/2025B. RileyInitiated CoverageBuy$4.00
1/7/2025B. RileyUpgradeStrong-Buy
12/10/2024HC WainwrightInitiated CoverageBuy$6.50
Slide 3
Back to 2
Continue to 4
 

More From MarketBeat
How to invest in Elon Musk’s Optimus before its launch
Elon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...
InvestorPlace | Sponsored
13 Stocks With Strong Institutional Buying
Hedge funds, university endowments, pension funds, and sovereign wealth funds have been pouring money into an ...
MarketBeat
Is he more powerful than Trump?
Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...
Porter & Company | Sponsored
15 Stocks That Insiders Won't Stop Buying
An insider trade occurs when a corporate executive (such as a CEO, CFO or COO) that has non-public information...
MarketBeat
Trump and Buffett Are Quietly Leading America’s Gold Revival
The “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...
Golden Portfolio | Sponsored
7 Cybersecurity Investments to Protect Your Portfolio, Your Data
Investors who were adults before the dawn of the internet can be forgiven for being amazed, and sometimes be...
MarketBeat